IP Library Patent Application 18212720
Patent Application
App. No. 18/212,720

Medical Treatments Based on Anamorelin

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/212,720
Abstract

Methods of treating cancer related conditions using anamorelin are described.

Claims (23)

1 . A method of treating cachexia in a human cancer patient comprising administering to said patient a therapeutically effective amount of anamorelin once daily for a therapeutically effective period of time.

2 . (canceled)

3 . (canceled)

4 . A method of treating fatigue resulting from cancer cachexia in a human cancer patient comprising administering to said patient a therapeutically effective amount of anamorelin on a daily basis for a therapeutically effective period of time.

5 . (canceled)

6 . (canceled)

7 . A method of increasing total body mass, lean body mass, and fat mass in a human patient suffering from cancer cachexia comprising administering to said patient a therapeutically effective amount of anamorelin on a daily basis for a therapeutically effective period of time.

8 . (canceled)

9 . The method of claim 4 wherein said fatigue is caused by depression, anemia, sarcopenia, anorexia, vomiting-related malnutrition, chemo-toxicity, opioid use, and/or sleep disturbances.

10 . The method of claim 1 wherein said human cancer patient is suffering from unresectable Stage III or IV non-small cell lung cancer and cachexia as defined by body weight loss greater than or equal to 5% in the previous 6 months or body mass index less than 20 kg/m 2 .

11 . The method of claim 1 wherein said therapeutically effective amount of anamorelin comprises 100 mg of anamorelin HCl based on the weight of the salt.

12 . The method of claim 1 wherein said therapeutically effective amount of anamorelin comprises 100 mg of anamorelin HCl based on the weight of the salt administered orally once daily at least one hour before the first meal.

13 . The method of claim 1 wherein said therapeutically effective amount of anamorelin is effective to increase lean body mass of said patient.

14 . The method of claim 1 wherein said therapeutically effective amount of anamorelin is effective to increase total body mass and lean body mass in said patient.

15 . The method of claim 1 wherein said therapeutically effective amount of anamorelin is effective to increase total body mass, lean body mass and fat mass of said patient.

16 . The method of claim 1 wherein said therapeutically effective period of time is twelve weeks.

17 . The method of claim 1 wherein said therapeutically effective period of time is from 13 to 24 weeks.

18 . The method of claim 1 wherein said patient has a performance status on the ECOG scale of 2 or higher.

19 . The method of claim 1 wherein said patient has a squamous tumor histology.

20 . The method of claim 1 wherein said cancer has metasticized.

21 . The method of claim 1 wherein said patient is not receiving chemotherapy or radiotherapy.

22 . The method of claim 1 wherein said patient is receiving chemotherapy or radiotherapy.

23 . The method of claim 1 wherein said patient is receiving opioids and/or antiemetics.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2024
From: MANN, WILLIAM; FRIEND, JOHN; LU, MING; DUUS, ELIZABETH; POLVINO, WILLIAM; ALLEN, SUZAN; GIORGINO, RUBEN; BARONI, ENRICO
To: HELSINN HEALTHCARE SA
Reel/Frame 067575/0435 →